Superseded sirtuin probe with real mouse pharmacology but no translational runway
Look, SRT1720 occupies a specific and somewhat awkward position in the sirtuin literature. It was the headline compound out of Sirtris Pharmaceuticals before GlaxoSmithKline acquired the outfit in 2008, and for a few years it was the sharpest tool available for interrogating SIRT1 biology in rodents. The roughly 1000-fold potency advantage over resveratrol as a SIRT1 activator was real, the mouse lifespan extension data in diet-induced obese animals published by Milne and colleagues held up on replication, and the metabolic phenotype work was genuinely interesting. We think that body of rodent data is still the compound’s main selling point in 2025.
Here’s the thing, though. The mechanism controversy matters. In 2010, Pacholec et al. published in the Journal of Biological Chemistry arguing that SRT1720 and related compounds were activating SIRT1 only in the context of fluorescent substrate assays, not with natural peptide substrates, implying the whole activation story was a biochemical artifact. That paper hit the field hard. The 2013 Hubbard et al. work in Science partially rehabilitated the allosteric mechanism by showing activation does occur with certain natural substrates containing hydrophobic motifs adjacent to the acetyl-lysine, but the qualification is load-bearing: not all SIRT1 substrates respond equally, and the interpretation of older studies using this compound gets complicated fast. Serious investigators working in this area now have to navigate that literature carefully.
The differentiation story is equally constrained. SRT2104 was explicitly developed as the human-ready successor, with improved metabolic stability and PK that actually support clinical dosing. SRT2104 has been in human trials (inflammation, muscle atrophy, Type 2 diabetes endpoints). SRT1720 has not. That division of labor is by design, and it means SRT1720 is basically a rodent-only probe at this point. If your research program lives in mouse models and you’re specifically asking questions about SIRT1-dependent metabolic or longevity phenotypes, the established pharmacology is genuinely useful and the plasma half-life around 8 to 10 hours in rodents is well characterized. Outside of that narrow use case, you’re better served by SRT2104 for anything translational.
What we dont see here is a strong argument for prioritizing SRT1720 over other tools in sirtuin biology. EX-527 handles the inhibitor side cleanly. SRT2104 handles the human-relevant activation angle. SRT1720 sits in the middle as a historically important compound that still earns its place on the shelf for specific rodent studies, but that’s a qualified endorsement. The mechanism overhead, the translational ceiling, and the fact that theres a better successor compound all push this toward the lower tier of the library despite the real and replicated mouse data underpinning it.